Overview

Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The study is a double-blind, randomized, placebo-controlled, Phase 2 clinical trial that will assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in healthy Indonesian soldiers deployed to eastern Indonesia.

Phase:

Phase 2

Details

Lead Sponsor:

Sanaria Inc.

Collaborators:

Congressionally Directed Medical Research Programs
Eijkman Oxford Clinical Research Unit, Indonesia
Indonesia University

Treatments:

Chloroquine
Chloroquine diphosphate